Atlas FDA

MEDSTONE STS LITHOTRIPTER

FDA premarket approval P970042/S002 · decided 2002-08-20

Approval details

PMA number
P970042
Supplement
S002
Supplement type
Normal 180 Day Track
Supplement reason
Labeling Change - Indications/instructions/shelf life/tradename
Trade name
MEDSTONE STS LITHOTRIPTER
Generic name
Lithotripter, shockwave (for treating gallbladder stones)
Applicant
Medstone Intl., Inc.
Date received
2002-02-21
Decision date
2002-08-20
Days to decision
180 days
Decision code
APPR
Product code
NCV
Advisory committee
Gastroenterology, Urology
Expedited review
No
Location
Aliso Viejo, CA
Statement
APPROVAL FOR 1) THE USE OF TWO GENERIC URSODIOLS, ONE MANUFACTURED BY AMIDE PHARMACEUTICAL AND ONE BY TEVA PHARMACEUTICAL, IN ADDITION TO ACTIGALL; 2) A CHANGE IN THE POST-APPROVAL STUDY'S MEDICAL MONITOR TO JOAN L. DRUCKER M.D., R.S.I.; AND 3) SEVERAL MINOR CLARIFICATIONS, CORRECTIONS AND EDITORIAL CHANGES TO THE POST-APPROVAL STUDY PROTOCOL. THE DEVICE, AS MODIFIED, WILL BE MARKETED UNDER THE SAME TRADE NAME, MEDSTONE STS LITHOTRIPTER, AND IS INDICATED FOR THE TREATMENT OF SYMPTOMATIC, SOLITAR

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
MEDSTONE, UROPRO 2000, TOMOGRAPHIC OPTION (K013620)Medstone Intl., Inc.2002-01-22
STS-T LITHOTRIPTER, MODEL STS-T (K010900)Medstone Intl., Inc.2001-04-05
STS(TM) FLUOROSCOPIC IMAGING MODULE (K905278)Medstone Intl., Inc.1991-02-04